Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

LONDON, February 19 /PRNewswire/ --

- Research Reveals the Impact Learning Platforms are Having on Decisions Regarding Content Purchases Within Schools

Over three quarters of ICT advisors in Local Authorities stated that it was very important that the content they purchased or schools' purchased was compatible with learning platforms used, according to new research from Shift Media.

The uptake of learning platforms continues apace in schools across England and Wales. Their implementation is certainly having an impact on the type of content which will be purchased by schools and local authorities, says Shift Media director Jane Powell.

SAN JOSE, California, February 19 /PRNewswire/ --

Atmel(R) Corporation (Nasdaq: ATML) and SEGGER Microcontroller, a leading manufacturer of middleware for embedded systems, announced today the availability of the real time operating system (OS) embOS for the AVR(R)32 microcontrollers.

The modern AVR32 architecture from Atmel is specially crafted to meet RTOS requirements with its fast multilevel interrupt controller, memory protection unit and the support for nested interrupts. Having an outstanding energy efficiency of 1.08 DMIPS/MHz and delivering up to 83 Dhrystone MIPS (DMIPS) performance at 66 MHz running from embedded flash the UC3 parts are among the highest performance flash microcontrollers in the market today.

ROCKVILLE, Maryland, February 19 /PRNewswire/ --

Pinnacle Biologics, a private, full-service pharmaceutical and biotech solutions company, today announced it has entered into an exclusive distribution agreement with MedImmune for Ethyol(R) (amifostine). The agreement, which is scheduled to take effect on June 1, 2008, grants Pinnacle Biologics exclusive Ethyol marketing authorization, certain licenses and distribution rights in Western Europe, Turkey and Israel. Additional terms of the agreement were not disclosed.

BERLIN, February 19 /PRNewswire/ --

- Introduction of New European Environmental Communication Programme - 'Product, Process and Planet'

GLASGOW, Scotland, February 19 /PRNewswire/ -- A Dundee lass who found herself homeless at aged 15 is one of six young people to be honoured tomorrow (Wednesday 20th February) as a "Scottish Achiever of the Year 2008."

Now a full-time hairdresser, Julie Hardie slept on friends' floors until a local shelter helped her to find a flat. Training charity Rathbone then taught her life-skills and combed job pages until she found work.

Open to all 1300 trainees at Rathbone Centres across Scotland, the Achievers Awards honour those who have made significant progress through learning. They will be presented at a glittering ceremony at the Scottish Parliament.

NEW HAVEN, Connecticut and KORTRIJK, Belgium, February 19 /PRNewswire/ --

- Natural Supplement for Attention-Deficit Hyperactivity Disorder in Children Fulfills Growing Need Throughout Asia -

RHEI Pharmaceuticals, Inc., a fully integrated specialty pharmaceuticals company focused on bringing proprietary medicines to the China market, and MethaPharma, part of then Vemedia Group, today announced that RHEI has licensed from MethaPharma the exclusive right to market and distribute Attental(R) throughout Asia. Attental is a nutraceutical currently commercially available in Europe for attention-deficit hyperactivity disorder (ADHD) in children.